Rodent tumor cells engineered to secrete cytokines such as interleukin 2 (IL-2) or IL-4 are rejected by syngeneic recipients due to an enhanced antitumor host immune response. An adenovirus vector (AdCAIL-2) containing the human IL-2 gene has been constructed and shown-to direct secretion of high levels of human IL-2 in infected tumor cells. AdCAIL-2 induces regression of tumors in a transgenic mouse model of mammary adenocarcinoma following intratumoral injection. Elimination of existing tumors in this way results in immunity against a second challenge with tumor cells. These findings suggest that adenovirus vectors expressing cytokines may form the basis for highly effective immunotherapies of human cancers.
Many tumor cells express various peptide antigens on their cell surface in association with major histocompatibility class I molecules (MHC I), and these antigens may allow immune effector cells to distinguish tumor from normal tissue (reviewed in ref. 1). Many of these tumor antigens have been isolated and shown to be recognized by human cytotoxic T lymphocyte (CTL) cell lines (2, 3) or tumor-infiltrating lymphocytes (TILs) (4, 5) . In addition, synthetic peptide epitopes displayed on the surface of tumor cells in association with MHC I molecules result in specific antitumor CTL activity (6) . Nevertheless, tumor cells known to express potentially antigenic peptides manage to evade host immunosurveillence and proliferate in vivo (2, 3, 7) . TILs are usually present in tumor biopsies but are unresponsive to the tumor antigens and fail to mediate cytotoxic activity (8) . It has been suggested that in some instances tumor cells may lack secondary costimulatory signals required to induce expression by immune effector cells of cytokines necessary for activation and proliferation of CTLs (9, 10) . This can result in anergy and thus failure of the T cells to respond to the antigen in a subsequent exposure. Indeed, it has been shown that CTL-mediated rejection of the tumor could be induced by transfection of melanoma tumor cells with DNA encoding the B7 costimulatory molecule (11) . In the absence of costimulatory signals, it may be possible to bypass this requirement by providing exogenous cytokines, the downstream effect of costimulation, and overcome or prevent anergy of the immune effector cells.
Many cytokines can mediate antitumor activity in vitro and in vivo (summarized in ref. 12) . Interleukin 2 (IL-2) has been demonstrated to possess antitumor activity through its ability to stimulate the cell-mediated killing activity of CTLs (13) , to induce lymphokine-activated killer cells (14, 15) , and to activate TILs (16, 17) . Systemic delivery of recombinant IL-2 has been used in animal models and in the clinic and has met with some success (reviewed in ref. 18 ). However, the short half-life of IL-2 in serum requires repeated high doses, resulting in severe side effects including vascular leak syndrome, edema, anemia, fevers and chills, nausea, and hypotension (reviewed in ref. 19 ). To avoid these problems, local delivery of low doses of IL-2 has been investigated in animal models and was found to mediate antitumor activity, resulting in increased survival and reduced tumor growth without the side effects associated with high dosing regimens (20, 21) . As a more effective method of achieving high intratumoral concentrations of IL-2, attention has turned to the use of gene delivery systems to express IL-2 continuously within or around the tumor. Transduction of tumor cells with retrovirus vectors expressing the IL-2 gene has been shown to reduce the tumorigenicity and metastatic potential of B16 melanomas (22) , CMS-5 fibrosarcoma (23, 24) , and the MBT-2 bladder carcinoma (25) . However, certain problems associated with the use of retroviral vectors (e.g., low titers, stability) have led us to examine adenovirus (Ad) vectors for immunotherapy of cancer.
The utility of adenoviruses (Ads) as gene therapy vectors is currently being intensively investigated (26) (27) (28) (29) (30) 
MATERIALS AND METHODS
Construction of Recombinant Plasmids and Viruses. Plasmids were constructed according to standard protocols (32) . The cDNA for hIL-2 was inserted between Xho I and EcoRI sites in the polylinker region of the shuttle plasmid pCA14 (33) to create pCAIL-2P. After purification by alkaline lysis (34) and cesium chloride density gradient banding, pCAIL-2P was cotransfected into 293 cells (35) with pBHG10 DNA (31) to generate AdCAIL-2 (see Fig. 1 Tumor-bearing transgenic mice were sacrificed and the tumors were explanted, minced, and incubated at 37°C with gentle stirring in collagenase/dispase solution [25 mg of collagenase and 250 mg of dispase (both from Boehringer Mannheim) in 100 ml of phosphate-buffered saline (PBS)]. Large clumps of cells were allowed to settle and the supernatant was centrifuged at 1500 rpm for 5 min at 4°C in a Beckman GPR centrifuge to pellet the cells. The pellets were resuspended in minimal essential medium (supplemented with penicillin/ streptomycin and L-glutamine) and 10% fetal bovine serum, and cells were plated at 107 per 150-mm tissue culture dish. After an overnight incubation to allow the cells to adhere, the tumor cell cultures were rinsed twice with PBS, fresh medium was added, and the cells were incubated for a further 24 hr. Intratumoral Injections of Ad Virus. Tumor cell cultures were prepared as described above but were not infected with virus. After incubation for 48 hr, the cells were harvested and 106 cells were injected s.c. into syngeneic mice. After 21 days, when palpable tumors had developed in all animals, the mice were injected intratumorally with 5 x 108 pfu of AdCAIL-2 or Addl70-3 in 100 ,ul of PBS or with PBS alone. Tumors were measured using calipers prior to injection of virus and at weekly intervals thereafter. Tumor size was estimated by determining the longest diameter and average width and calculating the volume assuming a prolate spheroid. 
RESULTS AND DISCUSSION
Kinetics of IL-2 Expression in Cells Infected with Ad-CAIL-2. The structure of AdCAIL-2 is illustrated in Fig. 1 (Fig. 2) . Most human cell lines were found to produce and secrete 1-2 ,ug of IL-2 per 106 infected cells over a period of 3-4 days, whereas expression by murine cells was 50-to 100-fold lower. The differences in expression between murine and human cell lines are likely due at least in part to the relatively lower activity of the HCMV IE promoter in murine cells compared to human cells (C.L.A. and F.L.G., unpublished). The levels of IL-2 produced, in the ng range, should nonetheless be sufficient for biological activity in treated animals.
In Vivo Modulation of Tumorigenicity. To determine whether expression of IL-2 by cells transduced with AdCAIL-2 could promote antitumor activity in vivo we chose to study a transgenic mouse model of mammary adenocarcinoma. Breast cancer affects one in nine women in North America and is the leading cause of death in nonsmoking women (42) . Although primary tumors can usually be surgically removed, the out- come of current therapies is often unsuccessful in preventing metastases (43) and 50% of women developing primary malignancy will eventually die from metastatic disease (44) . A majority of breast cancers have been shown to overexpress various oncogenes, such as c-neu (erbB-2) (reviewed in ref. 45) , and these molecules may be potential tumor antigens by which immune effector cells can distinguish tumor tissue from normal tissue. Breast cancer is therefore a prime target for treatment by immunotherapy whereby immune responses triggered against the tumor may result in the establishment of memory immune effector cells that recognize and destroy tumor cells and may prevent metastatic disease.
The transgenic mice possessing the PyMidT under the control of the mouse mammary tumor virus long terminal repeat develop adenocarcinoma of all mammary epithelium by 8-10 weeks of age. These tumors resemble the scirrhous carcinomas found in human breast cancers (45) , are heterogeneous, and will metastasize to the lungs. Cells from primary tumors can be explanted from the transgenic mice and treated with a collagenase/dispase solution to generate single cell suspensions that can be maintained in culture. Because the tumor cells express PyMidT they should be relatively immunogenic and, consistent with this, delivery of two consecutive doses of irradiated tumor cells i. per cell or were mock infected. After an additional 24 hr, by which time AdCAIL-2-infected cells had begun to express IL-2 ( Fig. 2) , syngeneic animals were injected s.c. with 106 infected tumor cells and monitored for tumor development (Fig. 3) . There was no significant difference in tumor onset in animals injected with mock-infected versus Addl70-3-infected cells, but a delay of 3-5 weeks was seen for animals receiving AdCAIL-2-infected cells. However, 100% of animals in all groups eventually developed tumors. Viral infection of tumor cells (with either Addl70-3 or AdCAIL-2) did not inhibit cell growth or proliferation in vitro, as determined by [3H]thymidine incorporation assays (data not shown), suggesting that the delay in tumor onset was not a result of cell killing due to viral infection or IL-2 production but was most likely due to IL-2-induced immune responses that were able to delay, but not prevent, tumor growth.
Regression of Established Tumors upon Intratumoral Injection. The ability of AdCAIL-2 infection to modify tumorigenicity led us to investigate the effect of local production of IL-2 in a more clinically relevant setting. Syngeneic animals were given 106 PyMidT cells s.c. and tumors were allowed to grow for 21 days, at which time all animals had developed palpable tumors -10 mm3 in size. Tumors were then directly injected with 5 x 108 pfu of AdCAIL-2, Addl70-3, or with PBS and mice were monitored for tumor growth ( PBS controls, possibly a result of anti-adenoviral immune responses generated against virus-infected cells (46) . However, all Addl70-3-injected tumors continued to enlarge until the mice became moribund (Fig. 4B) . In contrast, eight of nine tumors injected with AdCAIL-2 underwent complete regression, and by 3-4 weeks postinjection neither visible nor palpable tumors could be detected. Mice in which complete tumor regression occurred remained tumor free for 12 weeks postvirus injection, at which time they were used in a challenge experiment (see below). In the one mouse in which tumor regression failed to occur (dashed line in Fig. 4A ), the kinetics of tumor growth was not significantly different from that of the PBS control. This could reflect a failure to deliver virus efficiently into the tumor of this mouse or a subsequent leak of virus out of the site of injection.
Tumor-bearing animals that were injected with the same dose of virus s.c. in the flank opposite to that of the tumor failed to show any tumor regression or growth delay (data not shown), suggesting that IL-2 must be delivered intratumorally to mediate the effective immune responses. These results support the hypothesis that TILs within the tumor mass become activated and subsequently kill the tumor cells mediating regression. Histological sections of tumors 7 days postinjection with AdCAIL-2 showed a marked increase in lymphocytes present within the tumor compared to sections from control tumors, suggesting that IL-2 induces proliferation and accumulation of lymphocytes in the tumor (data not shown).
Results from the experiment of Fig. 4 and two additional experiments are presented in Table 1 . Although complete tumor regression was observed only in a minority of the animals treated in experiments 2 and 3, a pronounced delay in tumor growth was observed in most animals (87% for pooled data from all three experiments), and 54% of AdCAIL-2-treated tumors completely regressed. In animals showing a partial response, tumor development was significantly delayed and survival was increased for up to 6 weeks longer than for untreated animals or control virus-injected animals. Factors that might contribute to the variability in the response to AdCAIL-2 injection are the efficiency of delivery of the transducing virus to the tumor and its retention and dissemination within the tumor mass. In addition, the tumor cells are derived from different individual transgenic mice for each experiment and the variation noted between experiments may be due to differences in immune susceptibility of the tumor cells obtained from different animals.
AdCAIL-2-Treated Mice Are Protected from Tumor Challenge. It was important to determine whether mice in which tumors regressed were resistant to a second tumor cell challenge. Mice that underwent complete tumor regression were challenged with freshly isolated tumor cells 16 weeks postvirus injection (12 weeks after complete regression of primary tumors) by injection of 106 cells s.c. into the opposite flank. Untreated age-matched control animals were also injected with the tumor cell suspension to ensure the cell preparation possessed the potential to form solid tumors. All control mice (five in each experiment) developed tumors between days 15 and 21, whereas the experimental mice showed no sign of tumor development and are currently tumor free at 32 (eight mice) and 42 weeks (three mice) postchallenge in two independent experiments. Thus, mice in which tumors had regressed following AdCAIL-2 injection developed long-term immunity against a subsequent tumor challenge. This immunity is likely to be tumor specific, as it has been previously shown that animals that have been injected with IL-2-transduced tumor cells are protected from challenge with parental tumor cells but not from unrelated tumors (13, 23, 25) . In view of the fact that AdCAIL-2 transduction of tumor cells prior to injection resulted only in a delay in tumor development, the potency of AdCAIL-2 when directly injected into existing tumors is surprising. It would appear that the time and mode of delivery of AdCAIL-2 may be critically important in mediating tumor regression. This may reflect a requirement for immune effector cells to be recruited to the tumor site, primed, and activated, by which time the immune response may be insufficient or too late to completely abolish tumor growth. In contrast, when animals are tumor bearing, sufficient time has passed for recruitment and priming of immune effector cells within the tumor prior to cytokine treatment, and thus intratumoral expression of IL-2 at this point may be much more effective, resulting in activation of effector cells and potent antitumor activity. Our results suggest that in the intratumoral injection experiments, a resident effector cell population is present but does not respond to the tumor load and mediate regression. The delivery of IL-2 into the tumor results in the activation of this cell population and induces the potent antitumor responses seen. That not all tumors regressed when treated in this way may be a reflection of the use of primary tumor cells, which, like tumors in a clinical setting, may vary in their susceptibility to therapy. It is important to note that mice injected s.c. with PyMidT tumor cells always develop tumors at the site of injection and that the tumors have the potential to metastasize and never regress spontaneously. Thus ability to obtain regression of a majority of tumors by AdCAIL-2 administration is highly significant.
Fearon et al. (13) demonstrated that tumor cells secreting IL-2 could induce an antitumor activity that was dependent on CD8+ T cells and that this treatment could induce protective immunity. However, they found that this protection was short lived and that 50% of animals challenged 4 weeks after immunization developed tumors. In contrast, our findings that "cured" mice were protected against a challenge 3 months after primary tumor regression strongly suggest that these mice had developed a long-lasting immunity to the PyMidT tumor cells. Unlike cancer therapies that use cytotoxic genes or drugs to mediate tumor cell killing (47) (48) (49) (50) , this form of immunotherapy may generate immune responses that would lead to protection from distal secondary tumor development or metastases. Development of this form of immunity is extremely important for the treatment of cancers such as breast cancer and melanoma, where the patient usually succumbs to the metastatic spread of the disease. Recently, Haddada et al. (28) 
